ArticleBlood2017
miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.
Open access · greenAbstract read
In one paragraph
Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 66 citations in OpenAlex.
- T-cell miR-155 regulates the response to tumor-specific mRNA vaccines in a murine model of acute myeloid leukemia.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Assessing the contributions of noncoding RNAs in acute myeloid leukemia.Blood neoplasia · 2026Review
- Review
- The miRNA Landscape of Leukemia - Cellular Actions to Therapy through Molecular Mechanisms.Cell biochemistry and biophysics · 2025Review
- Novel molecular mechanisms of FLT3 deregulation: from the acute myeloid leukemia experience to therapeutic insights in acute lymphoblastic leukemia.Molecular cancer · 2025Review
- Functions, mechanisms, and therapeutic implications of noncoding RNA in acute myeloid leukemia.Fundamental research · 2025Review
- A microRNA-regulated transcriptional state defines intratumoral CD8Cell reports · 2025Article
- MicroRNAs Associated with a Bad Prognosis in Acute Myeloid Leukemia and Their Impact on Macrophage Polarization.Biomedicines · 2024Review
- Downregulation of stromal syntenin sustains AML development.EMBO molecular medicine · 2023Article
- Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update.Non-coding RNA · 2023Review
- Novel long non-coding RNAs associated with inflammation and macrophage activation in human.Scientific reports · 2023Article
- Interferon Gamma-Inducible NAMPT in Melanoma Cells Serves as a Mechanism of Resistance to Enhance Tumor Growth.Cancers · 2023Article
- Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.Signal transduction and targeted therapy · 2023Review
- The Promising Role of Non-Coding RNAs as Biomarkers and Therapeutic Targets for Leukemia.Genes · 2023Review
- Nef enhances HIV-1 replication and infectivity independently of SERINC5 in CEM T cells.Virology · 2023Article
- miRNA-1 promotes acute myeloid leukemia cell pathogenesis through metabolic regulation.Frontiers in genetics · 2023Article
- Circular RNAs: pivotal role in the leukemogenesis and novel indicators for the diagnosis and prognosis of acute myeloid leukemia.Frontiers in oncology · 2023Review
- MicroRNA profiling of paediatric AML withOncology reports · 2022Article
- Pathogenic Mechanisms in Acute Myeloid Leukemia.Current treatment options in oncology · 2022Review
- Recent insights into the microRNA and long non-coding RNA-mediated regulation of stem cell populations.3 Biotech · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Jared A WallaceDepartment of Pathology and.
Dominique A KageleDepartment of Pathology and.
Anna M EiringHuntsman Cancer Institute, University of Utah, Salt Lake City, UT.
Carissa N KimDepartment of Pathology and.
Ruozhen HuDepartment of Pathology and.
Marah C RuntschDepartment of Pathology and.
Margaret AlexanderDepartment of Pathology and.
Thomas B HuffakerDepartment of Pathology and.
Soh-Hyun LeeDepartment of Pathology and.
Ami B PatelHuntsman Cancer Institute, University of Utah, Salt Lake City, UT.
Timothy L MosbrugerHuntsman Cancer Institute, University of Utah, Salt Lake City, UT.
Warren P VothDepartment of Pathology and.
Dinesh S RaoDepartment of Pathology, University of California Los Angeles, Los Angeles, CA; and.
Rodney R MilesDepartment of Pathology and.
June L RoundDepartment of Pathology and.
Michael W DeiningerHuntsman Cancer Institute, University of Utah, Salt Lake City, UT.
Ryan M O'ConnellDepartment of Pathology and.
Huntsman Cancer Institute · USUniversity of Utah · USUniversity of California, Los Angeles · US
Funding
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6MRESEARCH TRAINING IN HEMATOLOGYT32DK007115 · NIDDK · UNIVERSITY OF UTAH · PI LEIBOLD, ELIZABETH ANN, PRCHAL, JOSEF T · 1986 to 2020
$8.4MInterdisciplinary Training Program in MetabolismT32DK091317 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI SCOTT A SUMMERS · 2011 to 2026
$4.8MMechanisms of resistance to ponatinib therapy in chronic myeloid leukemiaR01CA178397 · NCI · UNIVERSITY OF UTAH · PI DEININGER, MICHAEL W., O'HARE, THOMAS J. · 2014 to 2018
$2.6MCharacterizing tumor suppressive functions of microRNAs in B-cell neoplasiaR01CA166450 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAO, DINESH S · 2013 to 2017
$2.5MUtilizing TALEN technology to regulate human microRNA'sDP2GM111099 · NIGMS · UNIVERSITY OF UTAH · PI O'CONNELL, RYAN M · 2013 to 2013
$2.2MInvestigating the role of miR-155 and the interferon response in FLT3-ITD+ AMLF30CA217027 · NCI · UNIVERSITY OF UTAH · PI WALLACE, JARED · 2017 to 2019
$140kNCI NIH HHS F30 CA217027NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA166450NCI NIH HHS R01 CA178397NIDDK NIH HHS T32 DK007115NIDDK NIH HHS T32 DK091317NIGMS NIH HHS DP2 GM111099
Abstract
FLT3-ITD
Indexed as
AnimalsCell Line, TumorCRISPR-Cas SystemsDisease Models, AnimalFemalefms-Like Tyrosine Kinase 3HumansInterferonsLeukemia, Myeloid, AcuteMaleMiceMice, Inbred C57BLMice, KnockoutMice, Mutant StrainsMicroRNAsMutationFLT3 protein, humanFlt3 protein, mousefms-Like Tyrosine Kinase 3InterferonsMicroRNAsMIRN155 microRNA, humanMirn155 microRNA, mouse
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.